gp100 (87–95) is a 9-amino-acid fragment of human gp100/PMEL with the sequence ALNFPGSQK. Unlike many commonly studied gp100 epitopes that are HLA-A2 restricted, this peptide has been characterized in the context of the HLA-A3 supertype, including HLA-A3 and HLA-A11.

This different HLA profile gives AS2706 a distinct role within a melanoma antigen panel and makes it useful when research is not limited to HLA-A*02:01 systems.

Product Information

HLA-A3 Supertype Research

Early peptide-pulsed dendritic-cell studies showed that gp100 (87–95) could generate CTLs capable of recognizing gp100-positive melanoma cells in an HLA-A3 context. The same peptide also demonstrated high-affinity binding and functional recognition in HLA-A11-associated systems.

Subsequent immunopeptidomic work provided additional evidence that ALNFPGSQK can be naturally processed and presented, including association with HLA-A3 and HLA-A11.

Building Multi-HLA Antigen Panels

This characteristic makes AS2706 useful when assembling epitope panels that extend beyond the large group of HLA-A2-restricted melanoma peptides.

Researchers can compare it with HLA-A2-associated gp100 and MART-1 sequences in our Tumor-Associated Antigen Peptides collection.

For antigen-presentation, T-cell stimulation, and epitope-mapping workflows, see our Peptide Applications.

Purity and Laboratory Planning

For cellular immune assays, We recommend selecting purity according to the sensitivity of the downstream experiment and maintaining lot-specific analytical records where reproducibility across experiments is important.

Additional guidance is available through Recommended Peptide Purity.

Storage and Handling

Keep the lyophilized peptide protected from moisture and store it according to the applicable batch documentation. Reconstituted material should be handled under conditions appropriate to the intended immunological assay.

Research Use Only

gp100 (87–95), human is supplied for research use only. It is not intended for therapeutic, or human use.